overactive bladder
Urology · 2007–2023
5decisions
4medicines
0carried consumer input
0individual submissions
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| oxybutynin Treatment of detrusor overactivity (overactive bladder) in patients unable to tolerate or swallow oral oxybutynin. | Nov 2023 | Recommended with restriction | none received |
| botulinum toxin type A Treatment of urinary incontinence due to idiopathic overactive bladder (iOAB) in patients with ≥14 episodes/week, willing to self-catheterise, and who have… | Nov 2013 | Recommended with restriction | unclear |
| oxybutynin Treatment of symptoms of urge urinary incontinence and urgency in patients with overactive bladder. | Mar 2008 | Not recommended | no section in document |
| solifenacin Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency or increased frequency in patients where treatment with oxybutynin has… | Jul 2007 | Recommended | no section in document |
| solifenacin succinate Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency or increased urinary frequency in patients where treatment with oxybutynin… | Jul 2007 | Recommended | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.